



Approved for use through 10/31/2002. OMB 0651-0031

to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 2

Application Number	10/734,800
Filing Date	December 12, 2003
First Named Inventor	Carruthers
Group Art Unit	
Examiner Name	
Attorney Docket Number	PRD 2019

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/734,800
Filing Date	December 12, 2003
First Named Inventor	Carruthers
Group Art Unit	
Examiner Name	
Attorney Docket Number	PRD 2019

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BD		ALO, B.I. et al. Sequential Directed Ortho Metalation-Boronic Acid Cross Coupling Reactions. A General Regiospecific Route to Oxygenated Dibenzof[d]pyran-8-ones Related to Ellagic Acid. J. Org. Chem. 1991, 56:3763-3768.	
BD		AMMOUN, S. et al. Distinct Recognition of OX1 and OX2 Receptors by Orexin Peptides. J. Pharmacol. Exp. Ther. 2003, 305(2):507-514.	
BD		BLANCO, M. et al. Cellular Localization of Orexin Receptors in Human Pituitary. J. Clin. Endocrinol. Metab. 2001, 88(4):1616-1619.	
BD		CHEMELLI, R.M. et al. Narcolepsy in Orexin Knockout Mice: Molecular Genetics and Sleep Regulation. Cell 1999, 98(4):437-451.	
BD		CHEN, C.-T. et al. Pressor Effects of Orexins Injected Intracisternally and to Rostral Ventrolateral Medulla of Anesthetized Rats. Am. J. Physiol. 2000, 278(3):R692-R697.	
BD		DROUOT, X. et al. Low Levels of Ventricular CSF Orexin/Hypocretin in Advanced PD. Neurology 2003, 61(4):540-543.	
BD		FULTS, D. et al. Establishment and Characterization of a Human Primitive Neuroectodermal Tumor Cell Line from the Cerebral Hemisphere. J. Neuropathol. Exp. Neurol. 1992, 51(3):272-280.	
BD		HARA, J. Genetic Ablation of Orexin Neurons in Mice Results in Narcolepsy, Hypophagia, and Obesity. Neuron 2001, 30(2):345-354.	
BD		KIRCHGESSNER, A.L. and M.-T. LIU. Orexin Synthesis and Response in the Gut. Neuron 1999, 24(4):941-951.	
BD		LARSSON, K.P. et al. The STC-1 Cells Express Functional Orexin-A Receptors Coupled to CCK Release. Biochem. Biophys. Res. Commun. 2003, 309(1):209-218.	
BD		LIN, L. et al. The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) 2 Receptor Gene. Cell 1999, 98(3):365-378.	
BD		LUBKIN, M. and A. STRICKER-KRONGRAD. Independent Feeding and Metabolic Actions of Orexins in Mice. Biochem. Biophys. Res. Commun. 1998, 253(2):241-245.	
BD		MIGNOT, E. et al. Complex HLA-DR and -DQ Interactions Confer Risk of Narcolepsy-Cataplexy in Three Ethnic Groups. Am. J. Hum. Genet. 2001, 68(3):686-699.	
BD		MIGNOT, E. and E. THORSBY. Narcolepsy and the HLA System. N. Engl. J. Med. 2001, 344(8):892.	
BD		MIYAUURA, N. and A. SUZUKI. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. Chem. Rev. 1995, 95:2457-2483.	
BD		NAKAMURA, T. et al. Orexin-Induced Hyperlocomotion and Stereotypy Are Mediated by the Dopaminergic System. Brain Res. 2000, 873(1):181-187.	
BD		NORDIN, I.C. and J.A. THOMAS. An Improved Synthesis of (4S,5S)-2,2-Dimethyl-4-phenyl-1,3-dioxan-4-amine. Tetrahedron Lett. 1984, 25(50):5723-5724.	
BD		PEYRON, C. et al. Neurons Containing Hypocretin (Orexin) Project to Multiple Neuronal Systems. J. Neurosci. 1998, 18(23):9996-10015.	
BD		PEYRON, C. et al. A Mutation in a Case of Early Onset Narcolepsy and a Generalized Absence of Hypocretin Peptides in Human Narcoleptic Brains. Nat. Med. 2000, 6(9):991-997.	
BD		PIPER, D.C. et al. The Novel Brain Neuropeptide, Orexin-A, Modulates the Sleep-Wake Cycle of Rats. Eur. J. Neurosci. 2000, 12(2):726-732.	
BD		SAKURAI, T. et al. Orexin and Orexin Receptors: A Family of Hypothalamic and G Protein-Coupled Receptors that Regulate Feeding Behavior. Cell 1998, 92(4):573-585.	
BD		SAMSON, W.K. et al. Cardiovascular Regulatory Actions of the Hypocretins in Brain. Brain Res. 1999, 831(1-2):248-253.	
BD		SHIRASAKA, T. et al. Sympathetic and Cardiovascular Actions of Orexins in Conscious Rats. Am. J. Physiol. 1999, 277(6, Pt 2):R1780-R1785.	
BD		TAKAHASHI, N. et al. Stimulation of Gastric Acid Secretion by Centrally Administered Orexin-A in Conscious Rats. Biochem. Biophys. Res. Commun. 1999, 254(3):623-627.	
BD		VAN DEN POL, A.N. Hypothalamic Hypocretin (Orexin): Robust Innervation of the Spinal Cord. J. Neurosci. 1999, 19(8):3171-3182.	
BD		WILLIE, J.T. et al. Distinct Narcolepsy Syndromes in Orexin Receptor-2 and Orexin Null Mice: Molecular Genetic Dissection of Non-REM and REM Sleep Regulatory Processes. Neuron 2003, 38(5):715-730.	
BD		YAMANAKA, A. et al. Orexins Activate Histaminergic Neurons via the Orexin 2 Receptor. Biochem. Biophys. Res. Commun. 2002, 290(4):1237-1245.	

Examiner Signature	<i>B. Carruthers</i>	Date Considered	12-21-2004
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	10/734,800
Filing Date	December 12, 2003
First Named Inventor	Nicholas I. Carruthers et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	PRD-2019

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature	<i>B. Smith</i>	Date Considered	12-21-2004
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.